scispace - formally typeset
Open AccessJournal Article

Diagnosis and management of psoriasis

Reads0
Chats0
TLDR
Recognition of psoriasis, as well as its associated medical and psychiatric comorbidities, would facilitate timely diagnosis and appropriate management with effective and safe topical therapies and other medical and psychological interventions, as needed.
Abstract
Objective To provide primary care clinicians with an up-to-date and practical overview of the diagnosis and management of psoriasis. Quality of evidence PubMed, MEDLINE, EMBASE, and Cochrane databases were searched for relevant meta-analyses, randomized controlled trials, systematic reviews, and observational studies about the diagnosis and management of psoriasis. Main message Psoriasis is a chronic, multisystem inflammatory disease with predominantly skin and joint involvement. Beyond the physical dimensions of disease, psoriasis has an extensive emotional and psychosocial effect on patients, affecting social functioning and interpersonal relationships. As a disease of systemic inflammation, psoriasis is associated with multiple comorbidities, including cardiovascular disease and malignancy. The diagnosis is primarily clinical and a skin biopsy is seldom required. Depending on the severity of disease, appropriate treatment can be initiated. For mild to moderate disease, first-line treatment involves topical therapies including corticosteroids, vitamin D3 analogues, and combination products. These topical treatments are efficacious and can be safely initiated and prescribed by primary care physicians. Patients with more severe and refractory symptoms might require further evaluation by a dermatologist for systemic therapy. Conclusion Many patients with psoriasis seek initial evaluation and treatment from their primary care providers. Recognition of psoriasis, as well as its associated medical and psychiatric comorbidities, would facilitate timely diagnosis and appropriate management with effective and safe topical therapies and other medical and psychological interventions, as needed. More severe and refractory cases might warrant referral to a dermatologist for further evaluation and possible systemic therapy.

read more

Citations
More filters
Journal ArticleDOI

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints

TL;DR: An overview of the approved and in-development biologics targeting this axis is offered, emphasising how the availability of the “target” in the diseased tissues could provide a plausible explanation for the heterogeneous clinical efficacy of these drugs, thus opening future perspective of personalised therapies.
Journal ArticleDOI

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.

TL;DR: This study provides an assessment of the comparative efficacy among treatments for moderate to severe plaque psoriasis by meta-analysis suggests that brodalumab, guselkumAB, ixekizuab, and risankizumab-rzaa were associated with the highest PASI response rates in both short-term and long-term therapy.
Journal ArticleDOI

Microneedle array systems for long-acting drug delivery

TL;DR: This review covered the different types of MNs loaded with different nano/biotherapeutics for long-acting delivery for a wide range of potential clinical applications and outlined the future development scenario of such long- acting MN delivery systems for different disease conditions to achieve improved clinical benefit.
Journal ArticleDOI

Localised and sustained intradermal delivery of methotrexate using nanocrystal-loaded microneedle arrays: Potential for enhanced treatment of psoriasis.

TL;DR: The methotrexate nanocrystals were developed for its localising and sustaining its release in at the application site in the skin compared to conventional oral route and incorporated into dissolving microneedles for intradermal delivery.
Journal ArticleDOI

Understanding the prospective of nano-formulations towards the treatment of psoriasis.

TL;DR: In a nutshell, nano-formulations remain established as a promising modality for treating psoriasis treatment as they propose better penetration, targeted delivery, enhanced safety, and efficacy.
References
More filters
Journal ArticleDOI

Pathogenesis and clinical features of psoriasis.

TL;DR: Comorbidities of psoriasis are attracting interest, and include impairment of quality of life and associated depressive illness, cardiovascular disease, and a seronegative arthritis known as psoriatic arthritis.
Journal ArticleDOI

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

TL;DR: This data indicates that once-weekly dosing with adalimumab is a safe and effective treatment for moderate to severe chronic plaque psoriasis in women with atypical immune response to chemotherapy.
Journal ArticleDOI

A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience

TL;DR: This study confirms that PsA is a chronic, progressive disease in the majority of patients despite clinical improvement with current DMARD treatment, PsA results in radiological damage in up to 47% of patients at a median interval of 2 yr.
Related Papers (5)